Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
68.30 USD   +4.42%
09/30Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year Outcomes from the Randomized Phase 3 OAKS and DERBY Trials
PU
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
GL
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about APELLIS PHARMACEUTICALS, INC.
09/30Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year O..
PU
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
GL
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
GL
09/30Apellis Pharmaceuticals, Inc. Announces 24-Month Phase 3 Post Hoc Results Showing Treat..
CI
09/30Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
GL
09/30Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
GL
09/16Transcript : Apellis Pharmaceuticals, Inc. Presents at BofA Securities Global..
CI
09/12Insider Sell: Apellis Pharmaceuticals
MT
09/12Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global H..
GL
09/12Wedbush Raises Price Target on Apellis Pharmaceuticals to $67 From $55, Sees Increased ..
MT
09/08Insider Sell: Apellis Pharmaceuticals
MT
09/08Stifel Nicolaus Adjusts Price Target on Apellis Pharmaceuticals to $65 From $60, Keeps ..
MT
09/07Insider Sell: Apellis Pharmaceuticals
MT
09/07Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
GL
09/07Transcript : Apellis Pharmaceuticals, Inc. Presents at Citi's 17th Annual Bio..
CI
More most relevant news
All news about APELLIS PHARMACEUTICALS, INC.
09/30Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year O..
PU
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
GL
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
GL
09/30Apellis Pharmaceuticals, Inc. Announces 24-Month Phase 3 Post Hoc Results Showing Treat..
CI
09/30Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
GL
09/30Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
GL
09/16Transcript : Apellis Pharmaceuticals, Inc. Presents at BofA Securities Global..
CI
09/12Insider Sell: Apellis Pharmaceuticals
MT
09/12Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global H..
GL
09/12Wedbush Raises Price Target on Apellis Pharmaceuticals to $67 From $55, Sees Increased ..
MT
More news
News in other languages on APELLIS PHARMACEUTICALS, INC.
08/24Apellis Pharmaceuticals, Inc. Annonce des résultats à 24 mois montrant des effets accru..
08/18Vente d'initiés : Apellis Pharmaceuticals
08/16Vente d'initiés : Apellis Pharmaceuticals
08/15Vente d'initiés : Apellis Pharmaceuticals
08/08Apellis Pharmaceuticals réduit sa perte au deuxième trimestre et augmente son chiffre d..
08/08Earnings Flash (APLS) APELLIS PHARMACEUTICALS annonce un chiffre d'affaires de 16,3 mil..
08/08Apellis Pharmaceuticals, Inc. annonce ses résultats pour le deuxième trimestre et le se..
08/02Vente d'initiés : Apellis Pharmaceuticals
07/27Apellis Pharmaceuticals conclut des accords pour échanger 75,6 millions de dollars d'ob..
07/21Vente d'initiés : Apellis Pharmaceuticals
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
09/12Wedbush Raises Price Target on Apellis Pharmaceuticals to $67 From $55, Sees Increased ..
MT
09/08Stifel Nicolaus Adjusts Price Target on Apellis Pharmaceuticals to $65 From $60, Keeps ..
MT
09/07B. Riley Downgrades IVERIC bio to Sell from Neutral After 'Disappointing' Data Which Re..
MT
08/25Analyst recommendations: Nvidia, Thermo Fisher Scientific, Danah..
MS
08/24Wedbush Adjusts Apellis Pharmaceuticals Price Target to $55 From $45, Maintains Neutral..
MT
More recommendations
Press releases
09/30Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year O..
PU
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
GL
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
GL
09/30Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
GL
09/30Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
GL
More press releases
Upcoming event on APELLIS PHARMACEUTICALS, INC.